EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access

Photothermal‐Activated Platelet‐Rich Plasma Versus Conventional Platelet‐Rich Plasma for Melasma: A Split‐Face, Double‐Blind Randomized Controlled Trial

Rueangrit Siriphanit iD, Nattachar Ranoppawan, Sasin Charoensuksira iD, Wilai Thanasarnaksorn iD, Atchima Suwanchinda iD, Jitlada Meephansan iD

Photodermatology, Photoimmunology & Photomedicine · 2026

DOI: 10.1111/phpp.70122 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Photodermatology, Photoimmunology & Photomedicine, 2026. Verfasst von Rueangrit Siriphanit und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathum Thani, Thailand. Hauptthemen laut MEDLINE: Melanosis, Platelet-Rich Plasma, Low-Level Light Therapy. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Chulabhorn International College of Medicine, Chulabhorn International College of Medicine, Thammasat University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Melasma is a common acquired pigmentary disorder that predominantly affects women with darker skin types and substantially impairs quality of life. Current treatments are limited by variable efficacy, adverse effects, and frequent recurrence. Platelet‐rich plasma (PRP) has emerged as a potential regenerative treatment through growth‐factor–mediated modulation of melanogenesis. Photothermal activation, which combines photobiomodulation with controlled hypothermic conditioning, has been hypothesized to promote a more sustained growth‐factor release than conventional PRP. This study compared the efficacy and safety of photothermal‐activated PRP (PT‐PRP) and conventional PRP (C‐PRP) for melasma treatment.

Methods

This split‐face, double‐blind, randomized controlled trial included 26 women with epidermal or mixed‐type melasma. Each participant received three monthly sessions of intradermal PRP, with PT‐PRP and C‐PRP injected into opposite facial sides. Outcomes were assessed at weeks 0, 4, 8, and 12 using the modified Melasma Area and Severity Index (mMASI), Mexameter melanin and erythema indices, patient satisfaction, overall improvement, and adverse events.

Results

Both treatments significantly reduced mMASI by week 12, with no significant between‐group differences at any time point. C‐PRP showed significant mMASI improvement from week 4, whereas PT‐PRP reached significance from week 8. For the melanin index, PT‐PRP produced a significant within‐group reduction at week 12, while C‐PRP did not. At week 12, PT‐PRP showed a significantly lower melanin index than C‐PRP. Mild injection‐site bruising was the only adverse event.

Conclusion

PT‐PRP and C‐PRP produced comparable clinical improvement, but PT‐PRP achieved greater objective melanin reduction at week 12. PT‐PRP may represent a safe alternative treatment for melasma. Trial Registration Thai Clinical Trials Registry: TCTR20260318004

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanosisPlatelet-Rich PlasmaLow-Level Light TherapyHumansFemaleDouble-Blind MethodAdultMiddle Aged

Stichwörter der Autor:innen

melanin indexmelasmaphotobiomodulationphotothermal activationplatelet‐rich plasma

Autor:innen und Institutionen

  • Division of Dermatology, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathum Thani, Thailand.
  • Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Samitivej Sukhumvit Hospital, Bangkok Dusit Medical Services PLC, Bangkok, Thailand.

ORCID-Profile: Rueangrit Siriphanit, Sasin Charoensuksira, Wilai Thanasarnaksorn, Atchima Suwanchinda, Jitlada Meephansan

Förderung

  • Chulabhorn International College of Medicine
  • Chulabhorn International College of Medicine, Thammasat University

Zitieren

APA

Siriphanit, R., Ranoppawan, N., Charoensuksira, S., Thanasarnaksorn, W., Suwanchinda, A., & Meephansan, J. (2026). Photothermal‐Activated Platelet‐Rich Plasma Versus Conventional Platelet‐Rich Plasma for Melasma: A Split‐Face, Double‐Blind Randomized Controlled Trial. Photodermatology, Photoimmunology & Photomedicine. https://doi.org/10.1111/phpp.70122

Vancouver

Siriphanit R, Ranoppawan N, Charoensuksira S, Thanasarnaksorn W, Suwanchinda A, Meephansan J. Photothermal‐Activated Platelet‐Rich Plasma Versus Conventional Platelet‐Rich Plasma for Melasma: A Split‐Face, Double‐Blind Randomized Controlled Trial. Photodermatology, Photoimmunology & Photomedicine. 2026. doi:10.1111/phpp.70122

BibTeX
@article{Siriphanit2026,
  author = {Siriphanit, Rueangrit and Ranoppawan, Nattachar and Charoensuksira, Sasin and Thanasarnaksorn, Wilai and Suwanchinda, Atchima and Meephansan, Jitlada},
  title = {Photothermal‐Activated Platelet‐Rich Plasma Versus Conventional Platelet‐Rich Plasma for Melasma: A Split‐Face, Double‐Blind Randomized Controlled Trial},
  journal = {Photodermatology, Photoimmunology & Photomedicine},
  year = {2026},
  doi = {10.1111/phpp.70122}
}
Kostenlos starten →